NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/30/2026
Back to search
Official data from USPTO
TMOD
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
53
Latest update
06/30/2026
Trademark type
Word
Nice classes
5, 40, 42
Filing date
12/09/2020
Registration date
06/30/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/30/2026
Last transaction
06/30/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
05/01/2023
First use in commerce
05/01/2023
Drawing code
4
Owner type
03
Owner location
Agoura Hills, CA, US
Examiner
KELLY, JOHN M
Law office
N10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
A2 Biotherapeutics, Inc.
Representatives
Joi A. White CARR & FERRELL LLP
Technical classification
Nice Classes
Class 5Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
pharmaceutical products for the treatment and prevention of cancer; therapeutic targetsproteins or protein complexesfor the treatment and prevention of cancer; therapeutic cellstherapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of cancer; therapeutics and cell therapies in the nature of proteins and protein complexes for the treatment of cancer; engineered cell therapies in the nature of proteins and protein complexes for medical purposesthe treatment and prevention of cancer; engineered cell therapy platforms consisting of modified cellscell receptorsproteins and protein complexes; cell platforms consisting of modified cellscell receptorsproteins and protein complexes for the treatment and prevention of cancer; biological technology platforms consisting of modified cellscell receptorsproteins and protein complexes for developing and engineering therapeutic cellstherapeutic proteinstherapeutic antibodiestherapeutics and cellular therapies for the treatment and prevention of cancer; cell platform consisting of modified cellscell receptorsproteins and protein complexes for autologous and allogeneic cell manufacturing; therapeutics and cell therapies in the nature of proteins and protein complexes targeting targets lost in tumors for the treatment and prevention of cancer; gene therapy productsgenetically engineered tissues for transplant purposes
Class 40
custom manufacturing of cellstherapeutics and cell therapies for the treatment and prevention of cancer; biomanufacturing for othersmanufacturing of cellstherapeutics and cell therapies for the treatment and prevention of cancerusing biological cells in the manufacturing process; cell therapy manufacturing for others; autologous and allogeneic cell manufacturing for others; manufacturing services for others in the fields of therapeuticscell therapiesbiologicsmedicinepharmaceuticals; providing technical information in the field of pharmaceutical manufacturing; custom manufacturing of biological cellsproteinsantibodies for others for treatment and prevention of cancer
Class 42
Identification and development oftherapeutic targetsproteins and protein complexesfor others for the treatment and prevention of cancer; development of therapeutics and cell therapies for the treatment and prevention of cancer; development of therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer; biotechnology researchdevelopmenttesting and analysis for the treatment of cancer; scientific research and development services; providing scientific information in the fields of treatment and prevention of cancer; researchdevelopmentengineering and testing services in the fields of therapeuticscell therapiesbiologicsmedicinepharmaceuticals; medical laboratory servicestissue material processing and analysis in the field of autologous and allogeneic biologic preparations for medical use; biotechnology laboratory services; scientific and medical laboratory services; genetic engineering services; engineering of biological cellscellular targetsproteinsantibodies for others
Publications
History of USPTO decisions and trademark events.
53 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
06/30/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
06/08/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
06/08/2026
SUPC
STATEMENT OF USE PROCESSING COMPLETE
04/21/2026
IUAF
USE AMENDMENT FILED
11/24/2025
EISU
TEAS STATEMENT OF USE RECEIVED
11/24/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
08/12/2025
EX5G
SOU EXTENSION 5 GRANTED
08/11/2025
EXT5
SOU EXTENSION 5 FILED
05/14/2025
EEXT
SOU TEAS EXTENSION RECEIVED
05/14/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
10/22/2024
EX4G
SOU EXTENSION 4 GRANTED
10/22/2024
EXT4
SOU EXTENSION 4 FILED
10/22/2024
EEXT
SOU TEAS EXTENSION RECEIVED
10/22/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/15/2024
EX3G
SOU EXTENSION 3 GRANTED
05/14/2024
EXT3
SOU EXTENSION 3 FILED
05/14/2024
EEXT
SOU TEAS EXTENSION RECEIVED
05/14/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/21/2023
EX2G
SOU EXTENSION 2 GRANTED
11/17/2023
EXT2
SOU EXTENSION 2 FILED
11/17/2023
EEXT
SOU TEAS EXTENSION RECEIVED
11/17/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/11/2023
EX1G
SOU EXTENSION 1 GRANTED
05/09/2023
EXT1
SOU EXTENSION 1 FILED
05/09/2023
EEXT
SOU TEAS EXTENSION RECEIVED
05/09/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
11/22/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/27/2022
PUBO
PUBLISHED FOR OPPOSITION
09/27/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/07/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/18/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/18/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/17/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/17/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/13/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/13/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/13/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/22/2022
GNRT
NON-FINAL ACTION E-MAILED
05/22/2022
CNRT
NON-FINAL ACTION WRITTEN
05/22/2022
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
04/06/2022
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
03/08/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/19/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/18/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/17/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/17/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/18/2021
GNRT
NON-FINAL ACTION E-MAILED
08/18/2021
CNRT
NON-FINAL ACTION WRITTEN
08/18/2021
DOCK
ASSIGNED TO EXAMINER
05/28/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/16/2021
NWAP
NEW APPLICATION ENTERED
12/12/2020
Continuous trademark protection
Get notified about every new filing that threatens TMOD or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.